nodes	percent_of_prediction	percent_of_DWPC	metapath
Levonorgestrel—PGR—Spironolactone—dilated cardiomyopathy	0.18	0.362	CbGbCtD
Levonorgestrel—SHBG—Spironolactone—dilated cardiomyopathy	0.173	0.347	CbGbCtD
Levonorgestrel—AR—Spironolactone—dilated cardiomyopathy	0.145	0.291	CbGbCtD
Levonorgestrel—Progesterone—Spironolactone—dilated cardiomyopathy	0.0901	0.215	CrCrCtD
Levonorgestrel—Testosterone Propionate—Spironolactone—dilated cardiomyopathy	0.0901	0.215	CrCrCtD
Levonorgestrel—Methyltestosterone—Spironolactone—dilated cardiomyopathy	0.0879	0.209	CrCrCtD
Levonorgestrel—Testosterone—Spironolactone—dilated cardiomyopathy	0.0782	0.186	CrCrCtD
Levonorgestrel—Hydrocortisone—Spironolactone—dilated cardiomyopathy	0.0735	0.175	CrCrCtD
Levonorgestrel—Benign breast neoplasm—Spironolactone—dilated cardiomyopathy	0.0116	0.161	CcSEcCtD
Levonorgestrel—Breast cancer—Spironolactone—dilated cardiomyopathy	0.00332	0.0463	CcSEcCtD
Levonorgestrel—Hypertrichosis—Spironolactone—dilated cardiomyopathy	0.00319	0.0445	CcSEcCtD
Levonorgestrel—Menstruation irregular—Spironolactone—dilated cardiomyopathy	0.00219	0.0305	CcSEcCtD
Levonorgestrel—Polydipsia—Furosemide—dilated cardiomyopathy	0.00213	0.0297	CcSEcCtD
Levonorgestrel—Breast enlargement—Spironolactone—dilated cardiomyopathy	0.00187	0.0261	CcSEcCtD
Levonorgestrel—Breast pain—Spironolactone—dilated cardiomyopathy	0.00139	0.0194	CcSEcCtD
Levonorgestrel—Abdominal bloating—Furosemide—dilated cardiomyopathy	0.00139	0.0193	CcSEcCtD
Levonorgestrel—Amenorrhoea—Spironolactone—dilated cardiomyopathy	0.00138	0.0192	CcSEcCtD
Levonorgestrel—Cramps of lower extremities—Spironolactone—dilated cardiomyopathy	0.00111	0.0155	CcSEcCtD
Levonorgestrel—Leg pain—Lisinopril—dilated cardiomyopathy	0.00107	0.0149	CcSEcCtD
Levonorgestrel—Pelvic pain—Lisinopril—dilated cardiomyopathy	0.000814	0.0113	CcSEcCtD
Levonorgestrel—Influenza-like symptoms—Lisinopril—dilated cardiomyopathy	0.000693	0.00966	CcSEcCtD
Levonorgestrel—Otitis media—Lisinopril—dilated cardiomyopathy	0.000636	0.00887	CcSEcCtD
Levonorgestrel—ESR1—LKB1 signaling events—SIK1—dilated cardiomyopathy	0.000635	0.0615	CbGpPWpGaD
Levonorgestrel—Cramps of lower extremities—Furosemide—dilated cardiomyopathy	0.000606	0.00845	CcSEcCtD
Levonorgestrel—Endocrine disorder—Lisinopril—dilated cardiomyopathy	0.000597	0.00833	CcSEcCtD
Levonorgestrel—Bladder pain—Furosemide—dilated cardiomyopathy	0.000597	0.00832	CcSEcCtD
Levonorgestrel—Lightheadedness—Furosemide—dilated cardiomyopathy	0.00059	0.00823	CcSEcCtD
Levonorgestrel—Erythema multiforme—Spironolactone—dilated cardiomyopathy	0.000576	0.00803	CcSEcCtD
Levonorgestrel—Breast pain—Lisinopril—dilated cardiomyopathy	0.000568	0.00791	CcSEcCtD
Levonorgestrel—Protein urine present—Lisinopril—dilated cardiomyopathy	0.000556	0.00775	CcSEcCtD
Levonorgestrel—SHBG—Nongenotropic Androgen signaling—RAC1—dilated cardiomyopathy	0.000556	0.0539	CbGpPWpGaD
Levonorgestrel—Alopecia—Spironolactone—dilated cardiomyopathy	0.000538	0.0075	CcSEcCtD
Levonorgestrel—Vascular purpura—Furosemide—dilated cardiomyopathy	0.000536	0.00746	CcSEcCtD
Levonorgestrel—Muscle spasms—Spironolactone—dilated cardiomyopathy	0.00051	0.00711	CcSEcCtD
Levonorgestrel—Musculoskeletal pain—Lisinopril—dilated cardiomyopathy	0.000501	0.00699	CcSEcCtD
Levonorgestrel—Purpura—Furosemide—dilated cardiomyopathy	0.000497	0.00693	CcSEcCtD
Levonorgestrel—PGR—Nuclear Receptor transcription pathway—NR3C2—dilated cardiomyopathy	0.000496	0.0481	CbGpPWpGaD
Levonorgestrel—Cystitis noninfective—Lisinopril—dilated cardiomyopathy	0.000484	0.00674	CcSEcCtD
Levonorgestrel—Influenza like illness—Lisinopril—dilated cardiomyopathy	0.000481	0.0067	CcSEcCtD
Levonorgestrel—Cystitis—Lisinopril—dilated cardiomyopathy	0.000478	0.00666	CcSEcCtD
Levonorgestrel—Fluid retention—Lisinopril—dilated cardiomyopathy	0.00047	0.00655	CcSEcCtD
Levonorgestrel—Bladder pain—Lisinopril—dilated cardiomyopathy	0.000448	0.00624	CcSEcCtD
Levonorgestrel—Discomfort—Spironolactone—dilated cardiomyopathy	0.000446	0.00622	CcSEcCtD
Levonorgestrel—Lightheadedness—Lisinopril—dilated cardiomyopathy	0.000443	0.00618	CcSEcCtD
Levonorgestrel—Abdominal distension—Furosemide—dilated cardiomyopathy	0.000417	0.00581	CcSEcCtD
Levonorgestrel—Eczema—Lisinopril—dilated cardiomyopathy	0.0004	0.00557	CcSEcCtD
Levonorgestrel—ESR1—FOXM1 transcription factor network—LAMA4—dilated cardiomyopathy	0.0004	0.0387	CbGpPWpGaD
Levonorgestrel—Libido decreased—Lisinopril—dilated cardiomyopathy	0.000388	0.0054	CcSEcCtD
Levonorgestrel—Somnolence—Spironolactone—dilated cardiomyopathy	0.000385	0.00536	CcSEcCtD
Levonorgestrel—Pollakiuria—Furosemide—dilated cardiomyopathy	0.000382	0.00533	CcSEcCtD
Levonorgestrel—AR—Nuclear Receptor transcription pathway—NR3C2—dilated cardiomyopathy	0.000378	0.0366	CbGpPWpGaD
Levonorgestrel—Gastrointestinal disorder—Spironolactone—dilated cardiomyopathy	0.000374	0.00521	CcSEcCtD
Levonorgestrel—PGR—Nuclear signaling by ERBB4—PSEN2—dilated cardiomyopathy	0.000374	0.0362	CbGpPWpGaD
Levonorgestrel—SHBG—Nongenotropic Androgen signaling—RAF1—dilated cardiomyopathy	0.000368	0.0357	CbGpPWpGaD
Levonorgestrel—Pain in extremity—Lisinopril—dilated cardiomyopathy	0.000359	0.00501	CcSEcCtD
Levonorgestrel—Disturbance in sexual arousal—Lisinopril—dilated cardiomyopathy	0.000357	0.00497	CcSEcCtD
Levonorgestrel—AR—Regulation of nuclear SMAD2/3 signaling—ZBTB17—dilated cardiomyopathy	0.000354	0.0343	CbGpPWpGaD
Levonorgestrel—Urticaria—Spironolactone—dilated cardiomyopathy	0.000344	0.00479	CcSEcCtD
Levonorgestrel—Body temperature increased—Spironolactone—dilated cardiomyopathy	0.000342	0.00477	CcSEcCtD
Levonorgestrel—Urinary tract disorder—Furosemide—dilated cardiomyopathy	0.000327	0.00456	CcSEcCtD
Levonorgestrel—Urethral disorder—Furosemide—dilated cardiomyopathy	0.000325	0.00453	CcSEcCtD
Levonorgestrel—Breast disorder—Lisinopril—dilated cardiomyopathy	0.000325	0.00453	CcSEcCtD
Levonorgestrel—Visual impairment—Furosemide—dilated cardiomyopathy	0.000319	0.00445	CcSEcCtD
Levonorgestrel—Hypersensitivity—Spironolactone—dilated cardiomyopathy	0.000319	0.00444	CcSEcCtD
Levonorgestrel—SRD5A1—Metabolism of lipids and lipoproteins—ANKRD1—dilated cardiomyopathy	0.000313	0.0304	CbGpPWpGaD
Levonorgestrel—Erythema multiforme—Furosemide—dilated cardiomyopathy	0.000313	0.00437	CcSEcCtD
Levonorgestrel—Asthma—Lisinopril—dilated cardiomyopathy	0.000311	0.00433	CcSEcCtD
Levonorgestrel—Influenza—Lisinopril—dilated cardiomyopathy	0.000311	0.00433	CcSEcCtD
Levonorgestrel—Eye disorder—Furosemide—dilated cardiomyopathy	0.00031	0.00432	CcSEcCtD
Levonorgestrel—Pruritus—Spironolactone—dilated cardiomyopathy	0.000306	0.00427	CcSEcCtD
Levonorgestrel—Sweating increased—Lisinopril—dilated cardiomyopathy	0.000303	0.00422	CcSEcCtD
Levonorgestrel—Immune system disorder—Furosemide—dilated cardiomyopathy	0.000299	0.00417	CcSEcCtD
Levonorgestrel—Bronchitis—Lisinopril—dilated cardiomyopathy	0.000299	0.00416	CcSEcCtD
Levonorgestrel—Diarrhoea—Spironolactone—dilated cardiomyopathy	0.000296	0.00413	CcSEcCtD
Levonorgestrel—Arrhythmia—Furosemide—dilated cardiomyopathy	0.000296	0.00413	CcSEcCtD
Levonorgestrel—SRD5A1—Metabolism of lipids and lipoproteins—TAZ—dilated cardiomyopathy	0.000295	0.0286	CbGpPWpGaD
Levonorgestrel—ESR1—Nuclear Receptor transcription pathway—NR3C2—dilated cardiomyopathy	0.000291	0.0282	CbGpPWpGaD
Levonorgestrel—Dysuria—Lisinopril—dilated cardiomyopathy	0.00029	0.00405	CcSEcCtD
Levonorgestrel—Upper respiratory tract infection—Lisinopril—dilated cardiomyopathy	0.000289	0.00402	CcSEcCtD
Levonorgestrel—Malnutrition—Furosemide—dilated cardiomyopathy	0.000288	0.00402	CcSEcCtD
Levonorgestrel—Erythema—Furosemide—dilated cardiomyopathy	0.000288	0.00402	CcSEcCtD
Levonorgestrel—Dizziness—Spironolactone—dilated cardiomyopathy	0.000286	0.00399	CcSEcCtD
Levonorgestrel—Flatulence—Furosemide—dilated cardiomyopathy	0.000284	0.00396	CcSEcCtD
Levonorgestrel—Weight increased—Lisinopril—dilated cardiomyopathy	0.000283	0.00394	CcSEcCtD
Levonorgestrel—Weight decreased—Lisinopril—dilated cardiomyopathy	0.000281	0.00392	CcSEcCtD
Levonorgestrel—Pneumonia—Lisinopril—dilated cardiomyopathy	0.000279	0.00388	CcSEcCtD
Levonorgestrel—Muscle spasms—Furosemide—dilated cardiomyopathy	0.000277	0.00387	CcSEcCtD
Levonorgestrel—Depression—Lisinopril—dilated cardiomyopathy	0.000276	0.00385	CcSEcCtD
Levonorgestrel—Vomiting—Spironolactone—dilated cardiomyopathy	0.000275	0.00384	CcSEcCtD
Levonorgestrel—Rash—Spironolactone—dilated cardiomyopathy	0.000273	0.0038	CcSEcCtD
Levonorgestrel—Dermatitis—Spironolactone—dilated cardiomyopathy	0.000273	0.0038	CcSEcCtD
Levonorgestrel—ESR1—Regulation of nuclear SMAD2/3 signaling—ZBTB17—dilated cardiomyopathy	0.000273	0.0264	CbGpPWpGaD
Levonorgestrel—Headache—Spironolactone—dilated cardiomyopathy	0.000271	0.00378	CcSEcCtD
Levonorgestrel—Urinary tract infection—Lisinopril—dilated cardiomyopathy	0.000269	0.00375	CcSEcCtD
Levonorgestrel—Anaemia—Furosemide—dilated cardiomyopathy	0.000267	0.00372	CcSEcCtD
Levonorgestrel—Sinusitis—Lisinopril—dilated cardiomyopathy	0.00026	0.00362	CcSEcCtD
Levonorgestrel—Vertigo—Furosemide—dilated cardiomyopathy	0.000259	0.00361	CcSEcCtD
Levonorgestrel—Nausea—Spironolactone—dilated cardiomyopathy	0.000257	0.00358	CcSEcCtD
Levonorgestrel—Rhinitis—Lisinopril—dilated cardiomyopathy	0.000249	0.00347	CcSEcCtD
Levonorgestrel—Pharyngitis—Lisinopril—dilated cardiomyopathy	0.000247	0.00344	CcSEcCtD
Levonorgestrel—Urinary tract disorder—Lisinopril—dilated cardiomyopathy	0.000246	0.00342	CcSEcCtD
Levonorgestrel—Unspecified disorder of skin and subcutaneous tissue—Furosemide—dilated cardiomyopathy	0.000244	0.0034	CcSEcCtD
Levonorgestrel—Urethral disorder—Lisinopril—dilated cardiomyopathy	0.000244	0.0034	CcSEcCtD
Levonorgestrel—Erythema multiforme—Lisinopril—dilated cardiomyopathy	0.000235	0.00328	CcSEcCtD
Levonorgestrel—Shock—Furosemide—dilated cardiomyopathy	0.000232	0.00323	CcSEcCtD
Levonorgestrel—Nervous system disorder—Furosemide—dilated cardiomyopathy	0.000231	0.00322	CcSEcCtD
Levonorgestrel—Skin disorder—Furosemide—dilated cardiomyopathy	0.000229	0.00319	CcSEcCtD
Levonorgestrel—Hyperhidrosis—Furosemide—dilated cardiomyopathy	0.000228	0.00317	CcSEcCtD
Levonorgestrel—Anorexia—Furosemide—dilated cardiomyopathy	0.000224	0.00313	CcSEcCtD
Levonorgestrel—Mediastinal disorder—Lisinopril—dilated cardiomyopathy	0.000224	0.00312	CcSEcCtD
Levonorgestrel—AR—SIDS Susceptibility Pathways—SCN5A—dilated cardiomyopathy	0.000223	0.0216	CbGpPWpGaD
Levonorgestrel—Arrhythmia—Lisinopril—dilated cardiomyopathy	0.000222	0.0031	CcSEcCtD
Levonorgestrel—Alopecia—Lisinopril—dilated cardiomyopathy	0.00022	0.00306	CcSEcCtD
Levonorgestrel—ESR1—Nuclear signaling by ERBB4—PSEN2—dilated cardiomyopathy	0.000219	0.0213	CbGpPWpGaD
Levonorgestrel—Mental disorder—Lisinopril—dilated cardiomyopathy	0.000218	0.00304	CcSEcCtD
Levonorgestrel—Malnutrition—Lisinopril—dilated cardiomyopathy	0.000216	0.00302	CcSEcCtD
Levonorgestrel—Erythema—Lisinopril—dilated cardiomyopathy	0.000216	0.00302	CcSEcCtD
Levonorgestrel—Flatulence—Lisinopril—dilated cardiomyopathy	0.000213	0.00297	CcSEcCtD
Levonorgestrel—Tension—Lisinopril—dilated cardiomyopathy	0.000212	0.00296	CcSEcCtD
Levonorgestrel—Nervousness—Lisinopril—dilated cardiomyopathy	0.00021	0.00293	CcSEcCtD
Levonorgestrel—Back pain—Lisinopril—dilated cardiomyopathy	0.000209	0.00292	CcSEcCtD
Levonorgestrel—Somnolence—Furosemide—dilated cardiomyopathy	0.000209	0.00292	CcSEcCtD
Levonorgestrel—Muscle spasms—Lisinopril—dilated cardiomyopathy	0.000208	0.0029	CcSEcCtD
Levonorgestrel—Decreased appetite—Furosemide—dilated cardiomyopathy	0.000205	0.00285	CcSEcCtD
Levonorgestrel—Gastrointestinal disorder—Furosemide—dilated cardiomyopathy	0.000203	0.00283	CcSEcCtD
Levonorgestrel—Fatigue—Furosemide—dilated cardiomyopathy	0.000203	0.00283	CcSEcCtD
Levonorgestrel—ESR1—LKB1 signaling events—PSEN2—dilated cardiomyopathy	0.000203	0.0197	CbGpPWpGaD
Levonorgestrel—Constipation—Furosemide—dilated cardiomyopathy	0.000201	0.00281	CcSEcCtD
Levonorgestrel—Pain—Furosemide—dilated cardiomyopathy	0.000201	0.00281	CcSEcCtD
Levonorgestrel—Anaemia—Lisinopril—dilated cardiomyopathy	0.0002	0.00279	CcSEcCtD
Levonorgestrel—Angioedema—Lisinopril—dilated cardiomyopathy	0.000198	0.00276	CcSEcCtD
Levonorgestrel—Vertigo—Lisinopril—dilated cardiomyopathy	0.000194	0.00271	CcSEcCtD
Levonorgestrel—Syncope—Lisinopril—dilated cardiomyopathy	0.000194	0.00271	CcSEcCtD
Levonorgestrel—Gastrointestinal pain—Furosemide—dilated cardiomyopathy	0.000193	0.00268	CcSEcCtD
Levonorgestrel—Palpitations—Lisinopril—dilated cardiomyopathy	0.000191	0.00267	CcSEcCtD
Levonorgestrel—Loss of consciousness—Lisinopril—dilated cardiomyopathy	0.00019	0.00265	CcSEcCtD
Levonorgestrel—Cough—Lisinopril—dilated cardiomyopathy	0.000189	0.00263	CcSEcCtD
Levonorgestrel—Urticaria—Furosemide—dilated cardiomyopathy	0.000187	0.00261	CcSEcCtD
Levonorgestrel—Body temperature increased—Furosemide—dilated cardiomyopathy	0.000186	0.00259	CcSEcCtD
Levonorgestrel—Abdominal pain—Furosemide—dilated cardiomyopathy	0.000186	0.00259	CcSEcCtD
Levonorgestrel—Myalgia—Lisinopril—dilated cardiomyopathy	0.000184	0.00257	CcSEcCtD
Levonorgestrel—Chest pain—Lisinopril—dilated cardiomyopathy	0.000184	0.00257	CcSEcCtD
Levonorgestrel—Anxiety—Lisinopril—dilated cardiomyopathy	0.000184	0.00256	CcSEcCtD
Levonorgestrel—Unspecified disorder of skin and subcutaneous tissue—Lisinopril—dilated cardiomyopathy	0.000183	0.00255	CcSEcCtD
Levonorgestrel—CYP19A1—FSH signaling pathway—RPS6KB1—dilated cardiomyopathy	0.000183	0.0177	CbGpPWpGaD
Levonorgestrel—Discomfort—Lisinopril—dilated cardiomyopathy	0.000182	0.00254	CcSEcCtD
Levonorgestrel—Oedema—Lisinopril—dilated cardiomyopathy	0.000177	0.00246	CcSEcCtD
Levonorgestrel—Infection—Lisinopril—dilated cardiomyopathy	0.000176	0.00245	CcSEcCtD
Levonorgestrel—Shock—Lisinopril—dilated cardiomyopathy	0.000174	0.00242	CcSEcCtD
Levonorgestrel—Hypersensitivity—Furosemide—dilated cardiomyopathy	0.000173	0.00242	CcSEcCtD
Levonorgestrel—AR—Nongenotropic Androgen signaling—RAC1—dilated cardiomyopathy	0.000172	0.0167	CbGpPWpGaD
Levonorgestrel—Skin disorder—Lisinopril—dilated cardiomyopathy	0.000172	0.00239	CcSEcCtD
Levonorgestrel—Hyperhidrosis—Lisinopril—dilated cardiomyopathy	0.000171	0.00238	CcSEcCtD
Levonorgestrel—Asthenia—Furosemide—dilated cardiomyopathy	0.000169	0.00235	CcSEcCtD
Levonorgestrel—Anorexia—Lisinopril—dilated cardiomyopathy	0.000168	0.00235	CcSEcCtD
Levonorgestrel—Pruritus—Furosemide—dilated cardiomyopathy	0.000167	0.00232	CcSEcCtD
Levonorgestrel—Diarrhoea—Furosemide—dilated cardiomyopathy	0.000161	0.00225	CcSEcCtD
Levonorgestrel—Musculoskeletal discomfort—Lisinopril—dilated cardiomyopathy	0.000161	0.00224	CcSEcCtD
Levonorgestrel—Insomnia—Lisinopril—dilated cardiomyopathy	0.00016	0.00223	CcSEcCtD
Levonorgestrel—AR—SIDS Susceptibility Pathways—RYR2—dilated cardiomyopathy	0.000159	0.0154	CbGpPWpGaD
Levonorgestrel—Dyspnoea—Lisinopril—dilated cardiomyopathy	0.000157	0.0022	CcSEcCtD
Levonorgestrel—Somnolence—Lisinopril—dilated cardiomyopathy	0.000157	0.00219	CcSEcCtD
Levonorgestrel—Dizziness—Furosemide—dilated cardiomyopathy	0.000156	0.00217	CcSEcCtD
Levonorgestrel—Dyspepsia—Lisinopril—dilated cardiomyopathy	0.000156	0.00217	CcSEcCtD
Levonorgestrel—Decreased appetite—Lisinopril—dilated cardiomyopathy	0.000154	0.00214	CcSEcCtD
Levonorgestrel—Gastrointestinal disorder—Lisinopril—dilated cardiomyopathy	0.000153	0.00213	CcSEcCtD
Levonorgestrel—Fatigue—Lisinopril—dilated cardiomyopathy	0.000152	0.00212	CcSEcCtD
Levonorgestrel—Pain—Lisinopril—dilated cardiomyopathy	0.000151	0.00211	CcSEcCtD
Levonorgestrel—Constipation—Lisinopril—dilated cardiomyopathy	0.000151	0.00211	CcSEcCtD
Levonorgestrel—Vomiting—Furosemide—dilated cardiomyopathy	0.00015	0.00209	CcSEcCtD
Levonorgestrel—Rash—Furosemide—dilated cardiomyopathy	0.000148	0.00207	CcSEcCtD
Levonorgestrel—Dermatitis—Furosemide—dilated cardiomyopathy	0.000148	0.00207	CcSEcCtD
Levonorgestrel—Headache—Furosemide—dilated cardiomyopathy	0.000148	0.00206	CcSEcCtD
Levonorgestrel—Gastrointestinal pain—Lisinopril—dilated cardiomyopathy	0.000144	0.00201	CcSEcCtD
Levonorgestrel—ESR1—AP-1 transcription factor network—NPPA—dilated cardiomyopathy	0.000142	0.0137	CbGpPWpGaD
Levonorgestrel—Urticaria—Lisinopril—dilated cardiomyopathy	0.00014	0.00196	CcSEcCtD
Levonorgestrel—Nausea—Furosemide—dilated cardiomyopathy	0.00014	0.00195	CcSEcCtD
Levonorgestrel—Abdominal pain—Lisinopril—dilated cardiomyopathy	0.00014	0.00195	CcSEcCtD
Levonorgestrel—Body temperature increased—Lisinopril—dilated cardiomyopathy	0.00014	0.00195	CcSEcCtD
Levonorgestrel—SRD5A1—Metabolism—ANKRD1—dilated cardiomyopathy	0.00014	0.0135	CbGpPWpGaD
Levonorgestrel—AR—Integrated Pancreatic Cancer Pathway—PLN—dilated cardiomyopathy	0.000131	0.0127	CbGpPWpGaD
Levonorgestrel—SRD5A1—Metabolism—TAZ—dilated cardiomyopathy	0.000131	0.0127	CbGpPWpGaD
Levonorgestrel—Hypersensitivity—Lisinopril—dilated cardiomyopathy	0.00013	0.00181	CcSEcCtD
Levonorgestrel—PGR—Cellular roles of Anthrax toxin—TNF—dilated cardiomyopathy	0.000129	0.0125	CbGpPWpGaD
Levonorgestrel—Progesterone—NR3C2—dilated cardiomyopathy	0.000128	1	CrCbGaD
Levonorgestrel—Asthenia—Lisinopril—dilated cardiomyopathy	0.000127	0.00177	CcSEcCtD
Levonorgestrel—PGR—Signaling by ERBB4—PSEN2—dilated cardiomyopathy	0.000126	0.0122	CbGpPWpGaD
Levonorgestrel—Pruritus—Lisinopril—dilated cardiomyopathy	0.000125	0.00174	CcSEcCtD
Levonorgestrel—Diarrhoea—Lisinopril—dilated cardiomyopathy	0.000121	0.00168	CcSEcCtD
Levonorgestrel—SRD5A1—Metabolism—SDHA—dilated cardiomyopathy	0.000119	0.0115	CbGpPWpGaD
Levonorgestrel—Dizziness—Lisinopril—dilated cardiomyopathy	0.000117	0.00163	CcSEcCtD
Levonorgestrel—AR—Nongenotropic Androgen signaling—RAF1—dilated cardiomyopathy	0.000114	0.0111	CbGpPWpGaD
Levonorgestrel—Vomiting—Lisinopril—dilated cardiomyopathy	0.000112	0.00157	CcSEcCtD
Levonorgestrel—Rash—Lisinopril—dilated cardiomyopathy	0.000111	0.00155	CcSEcCtD
Levonorgestrel—Dermatitis—Lisinopril—dilated cardiomyopathy	0.000111	0.00155	CcSEcCtD
Levonorgestrel—Headache—Lisinopril—dilated cardiomyopathy	0.000111	0.00154	CcSEcCtD
Levonorgestrel—CYP19A1—FSH signaling pathway—RAF1—dilated cardiomyopathy	0.00011	0.0106	CbGpPWpGaD
Levonorgestrel—Nausea—Lisinopril—dilated cardiomyopathy	0.000105	0.00146	CcSEcCtD
Levonorgestrel—ESR1—Aryl Hydrocarbon Receptor—CD36—dilated cardiomyopathy	0.000103	0.00994	CbGpPWpGaD
Levonorgestrel—ESR1—Integrated Pancreatic Cancer Pathway—PLN—dilated cardiomyopathy	0.000101	0.00981	CbGpPWpGaD
Levonorgestrel—AR—Regulation of nuclear SMAD2/3 signaling—IL10—dilated cardiomyopathy	9.08e-05	0.0088	CbGpPWpGaD
Levonorgestrel—ESR1—AP-1 transcription factor network—GJA1—dilated cardiomyopathy	9.06e-05	0.00879	CbGpPWpGaD
Levonorgestrel—PGR—Generic Transcription Pathway—NR3C2—dilated cardiomyopathy	8.56e-05	0.0083	CbGpPWpGaD
Levonorgestrel—ESR1—AP-1 transcription factor network—IL10—dilated cardiomyopathy	7.86e-05	0.00762	CbGpPWpGaD
Levonorgestrel—ESR1—Regulation of Telomerase—RPS6KB1—dilated cardiomyopathy	7.82e-05	0.00759	CbGpPWpGaD
Levonorgestrel—AR—Androgen receptor signaling pathway—RAC1—dilated cardiomyopathy	7.4e-05	0.00717	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling by ERBB4—PSEN2—dilated cardiomyopathy	7.39e-05	0.00716	CbGpPWpGaD
Levonorgestrel—SRD5A1—Metabolism of lipids and lipoproteins—GPX1—dilated cardiomyopathy	7.24e-05	0.00702	CbGpPWpGaD
Levonorgestrel—ESR1—Leptin signaling pathway—RPS6KB1—dilated cardiomyopathy	7.23e-05	0.00701	CbGpPWpGaD
Levonorgestrel—SRD5A1—Metabolism of lipids and lipoproteins—CD36—dilated cardiomyopathy	7.05e-05	0.00684	CbGpPWpGaD
Levonorgestrel—ESR1—Regulation of nuclear SMAD2/3 signaling—IL10—dilated cardiomyopathy	6.99e-05	0.00678	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism of lipids and lipoproteins—ANKRD1—dilated cardiomyopathy	6.81e-05	0.0066	CbGpPWpGaD
Levonorgestrel—ESR1—AP-1 transcription factor network—AGT—dilated cardiomyopathy	6.6e-05	0.0064	CbGpPWpGaD
Levonorgestrel—ESR1—Leptin signaling pathway—RAC1—dilated cardiomyopathy	6.53e-05	0.00634	CbGpPWpGaD
Levonorgestrel—AR—Generic Transcription Pathway—NR3C2—dilated cardiomyopathy	6.52e-05	0.00632	CbGpPWpGaD
Levonorgestrel—ESR1—Aryl Hydrocarbon Receptor—RAF1—dilated cardiomyopathy	6.41e-05	0.00621	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism of lipids and lipoproteins—TAZ—dilated cardiomyopathy	6.4e-05	0.00621	CbGpPWpGaD
Levonorgestrel—SRD5A1—Metabolism of lipids and lipoproteins—AGT—dilated cardiomyopathy	6.35e-05	0.00616	CbGpPWpGaD
Levonorgestrel—AR—SIDS Susceptibility Pathways—GJA1—dilated cardiomyopathy	6.2e-05	0.00601	CbGpPWpGaD
Levonorgestrel—PGR—Generic Transcription Pathway—NPPA—dilated cardiomyopathy	5.38e-05	0.00521	CbGpPWpGaD
Levonorgestrel—AR—SIDS Susceptibility Pathways—IL10—dilated cardiomyopathy	5.37e-05	0.00521	CbGpPWpGaD
Levonorgestrel—ESR1—Generic Transcription Pathway—NR3C2—dilated cardiomyopathy	5.02e-05	0.00487	CbGpPWpGaD
Levonorgestrel—AR—Integrated Breast Cancer Pathway—RAC1—dilated cardiomyopathy	4.85e-05	0.0047	CbGpPWpGaD
Levonorgestrel—ESR1—Aryl Hydrocarbon Receptor—EGFR—dilated cardiomyopathy	4.39e-05	0.00426	CbGpPWpGaD
Levonorgestrel—ESR1—Leptin signaling pathway—RAF1—dilated cardiomyopathy	4.33e-05	0.0042	CbGpPWpGaD
Levonorgestrel—AR—Integrated Pancreatic Cancer Pathway—FASLG—dilated cardiomyopathy	4.25e-05	0.00412	CbGpPWpGaD
Levonorgestrel—PGR—Signaling by ERBB4—RAF1—dilated cardiomyopathy	4.2e-05	0.00407	CbGpPWpGaD
Levonorgestrel—ESR1—Aryl Hydrocarbon Receptor—TNF—dilated cardiomyopathy	4.18e-05	0.00406	CbGpPWpGaD
Levonorgestrel—CYP19A1—Integrated Breast Cancer Pathway—RAC1—dilated cardiomyopathy	4.17e-05	0.00404	CbGpPWpGaD
Levonorgestrel—PGR—Gene Expression—NR3C2—dilated cardiomyopathy	4.12e-05	0.004	CbGpPWpGaD
Levonorgestrel—AR—Generic Transcription Pathway—NPPA—dilated cardiomyopathy	4.1e-05	0.00397	CbGpPWpGaD
Levonorgestrel—AR—Integrated Pancreatic Cancer Pathway—FAS—dilated cardiomyopathy	4.1e-05	0.00397	CbGpPWpGaD
Levonorgestrel—AR—Integrated Pancreatic Cancer Pathway—RAC1—dilated cardiomyopathy	4.02e-05	0.00389	CbGpPWpGaD
Levonorgestrel—ESR1—Integrated Breast Cancer Pathway—RAC1—dilated cardiomyopathy	3.73e-05	0.00362	CbGpPWpGaD
Levonorgestrel—AR—Androgen receptor signaling pathway—EGFR—dilated cardiomyopathy	3.36e-05	0.00326	CbGpPWpGaD
Levonorgestrel—ESR1—Integrated Pancreatic Cancer Pathway—FASLG—dilated cardiomyopathy	3.27e-05	0.00317	CbGpPWpGaD
Levonorgestrel—SRD5A1—Metabolism—GPX1—dilated cardiomyopathy	3.22e-05	0.00313	CbGpPWpGaD
Levonorgestrel—ESR1—Regulation of Telomerase—EGFR—dilated cardiomyopathy	3.21e-05	0.00312	CbGpPWpGaD
Levonorgestrel—ESR1—Generic Transcription Pathway—NPPA—dilated cardiomyopathy	3.16e-05	0.00306	CbGpPWpGaD
Levonorgestrel—ESR1—Integrated Pancreatic Cancer Pathway—FAS—dilated cardiomyopathy	3.16e-05	0.00306	CbGpPWpGaD
Levonorgestrel—AR—Gene Expression—NR3C2—dilated cardiomyopathy	3.14e-05	0.00305	CbGpPWpGaD
Levonorgestrel—SRD5A1—Metabolism—CD36—dilated cardiomyopathy	3.14e-05	0.00304	CbGpPWpGaD
Levonorgestrel—ESR1—Integrated Pancreatic Cancer Pathway—RAC1—dilated cardiomyopathy	3.09e-05	0.003	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism—ANKRD1—dilated cardiomyopathy	3.03e-05	0.00294	CbGpPWpGaD
Levonorgestrel—PGR—Signaling by ERBB4—EGFR—dilated cardiomyopathy	2.88e-05	0.00279	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism—TAZ—dilated cardiomyopathy	2.85e-05	0.00276	CbGpPWpGaD
Levonorgestrel—SRD5A1—Metabolism—AGT—dilated cardiomyopathy	2.83e-05	0.00274	CbGpPWpGaD
Levonorgestrel—AR—Integrated Pancreatic Cancer Pathway—RAF1—dilated cardiomyopathy	2.66e-05	0.00258	CbGpPWpGaD
Levonorgestrel—PGR—Gene Expression—NPPA—dilated cardiomyopathy	2.59e-05	0.00251	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism—SDHA—dilated cardiomyopathy	2.58e-05	0.0025	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling by ERBB4—RAF1—dilated cardiomyopathy	2.46e-05	0.00239	CbGpPWpGaD
Levonorgestrel—ESR1—Gene Expression—NR3C2—dilated cardiomyopathy	2.42e-05	0.00235	CbGpPWpGaD
Levonorgestrel—AR—Integrated Breast Cancer Pathway—EGFR—dilated cardiomyopathy	2.2e-05	0.00214	CbGpPWpGaD
Levonorgestrel—ESR1—Integrated Pancreatic Cancer Pathway—RAF1—dilated cardiomyopathy	2.05e-05	0.00199	CbGpPWpGaD
Levonorgestrel—AR—SIDS Susceptibility Pathways—TNF—dilated cardiomyopathy	2.04e-05	0.00198	CbGpPWpGaD
Levonorgestrel—AR—Gene Expression—NPPA—dilated cardiomyopathy	1.97e-05	0.00191	CbGpPWpGaD
Levonorgestrel—CYP19A1—Integrated Breast Cancer Pathway—EGFR—dilated cardiomyopathy	1.9e-05	0.00184	CbGpPWpGaD
Levonorgestrel—AR—Integrated Pancreatic Cancer Pathway—EGFR—dilated cardiomyopathy	1.83e-05	0.00177	CbGpPWpGaD
Levonorgestrel—AR—Integrated Pancreatic Cancer Pathway—TNF—dilated cardiomyopathy	1.74e-05	0.00169	CbGpPWpGaD
Levonorgestrel—ESR1—Integrated Breast Cancer Pathway—EGFR—dilated cardiomyopathy	1.7e-05	0.00165	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling by ERBB4—EGFR—dilated cardiomyopathy	1.69e-05	0.00164	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—PSEN2—dilated cardiomyopathy	1.63e-05	0.00158	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism of lipids and lipoproteins—GPX1—dilated cardiomyopathy	1.57e-05	0.00152	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism of lipids and lipoproteins—CD36—dilated cardiomyopathy	1.53e-05	0.00148	CbGpPWpGaD
Levonorgestrel—ESR1—Gene Expression—NPPA—dilated cardiomyopathy	1.52e-05	0.00147	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—CXCL2—dilated cardiomyopathy	1.45e-05	0.0014	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—AGTR2—dilated cardiomyopathy	1.45e-05	0.0014	CbGpPWpGaD
Levonorgestrel—ESR1—Integrated Pancreatic Cancer Pathway—EGFR—dilated cardiomyopathy	1.41e-05	0.00136	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism of lipids and lipoproteins—AGT—dilated cardiomyopathy	1.38e-05	0.00134	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—CXCR3—dilated cardiomyopathy	1.35e-05	0.0013	CbGpPWpGaD
Levonorgestrel—ESR1—Integrated Pancreatic Cancer Pathway—TNF—dilated cardiomyopathy	1.34e-05	0.0013	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—ADRB1—dilated cardiomyopathy	1.3e-05	0.00126	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—AGTR1—dilated cardiomyopathy	1.11e-05	0.00108	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—ADRB2—dilated cardiomyopathy	1.06e-05	0.00102	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—PSEN2—dilated cardiomyopathy	9.57e-06	0.000928	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	9.07e-06	0.00088	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—ANKRD1—dilated cardiomyopathy	8.85e-06	0.000858	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—CXCL2—dilated cardiomyopathy	8.49e-06	0.000824	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—AGTR2—dilated cardiomyopathy	8.49e-06	0.000824	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—TAZ—dilated cardiomyopathy	8.32e-06	0.000806	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—RAC1—dilated cardiomyopathy	8.2e-06	0.000795	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—CXCR3—dilated cardiomyopathy	7.9e-06	0.000766	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—AGT—dilated cardiomyopathy	7.83e-06	0.000759	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—ADRB1—dilated cardiomyopathy	7.65e-06	0.000742	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—SDHA—dilated cardiomyopathy	7.52e-06	0.000729	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism—GPX1—dilated cardiomyopathy	7e-06	0.000679	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism—CD36—dilated cardiomyopathy	6.82e-06	0.000661	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—AGTR1—dilated cardiomyopathy	6.53e-06	0.000633	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—ADRB2—dilated cardiomyopathy	6.2e-06	0.000601	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism—AGT—dilated cardiomyopathy	6.14e-06	0.000595	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—RAF1—dilated cardiomyopathy	5.43e-06	0.000527	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	5.32e-06	0.000516	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—RAC1—dilated cardiomyopathy	4.81e-06	0.000466	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—AGT—dilated cardiomyopathy	4.6e-06	0.000446	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—EGFR—dilated cardiomyopathy	3.73e-06	0.000361	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—RAF1—dilated cardiomyopathy	3.19e-06	0.000309	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—EGFR—dilated cardiomyopathy	2.19e-06	0.000212	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—GPX1—dilated cardiomyopathy	2.04e-06	0.000198	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—CD36—dilated cardiomyopathy	1.99e-06	0.000193	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—AGT—dilated cardiomyopathy	1.79e-06	0.000174	CbGpPWpGaD
